Show
Sort by
-
- Journal Article
- A1
- open access
COVID-19 in adult acute myeloid leukemia patients : a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
-
- Journal Article
- A1
- open access
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : a European Hematology Association Survey (EPICOVIDEHA)
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial